Across TCGA pan-cancer cohorts, MRPL50P1 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MRPL50P1’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MRPL50P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRPL50P1 is over-expressed in tumor.
KIRC are the cancer types where MRPL50P1 tumor–normal differential expression is most reproducible.